RxDoctor Payments Data

Adam Woodruff, MD

Nephrology · Jonesboro, ARNPI 1538383799

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.2% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Baxter Healthcare at 30.7% of the total. That places this record below the midpoint for nephrology clinicians in AR, where the typical reported total is $925.

$358in general payments, 2019–2025

Across 17 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$110
  • Bayer$82
  • Medtronic$75
  • Aurinia Pharma U.S., Inc.$22
  • Travere Therapeutics, Inc.$20
  • Amgen$18
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$33493%
  • Education$247%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$358 in reported general payments places this provider in the 35th percentile of 85 nephrology providers in Arkansas.

See all nephrology providers in Arkansas

Medicare billing

Part B allowed, 2024
$323,179
Medicare patients
682
Services billed
7,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide21$70,645
XphozahTenapanor Hcl11$31,907
JardianceEmpagliflozin29$20,524
FarxigaDapagliflozin Propanediol39$20,459
MounjaroTirzepatide12$12,413
ProsolParenteral Amino Acid 20% No.120$4,266
Sevelamer Carbonate33$3,869
Nifedipine ErNifedipine158$2,522
Calcitriol154$2,494
Spironolactone349$2,398
Bumetanide34$1,518
Calcium Acetate13$1,422
Torsemide73$1,353
Tamsulosin Hcl109$1,320
Bisoprolol Fumarate62$1,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$13$20,52429 claims
AstraZenecaFarxiga$18$20,45939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 85 nephrology providers in Arkansas.

Other nephrology in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →